☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
VIVUS
VIVUS’ Qsymia Receives the US FDA’s Approval for the Treatment of Obesity in Adolescents Aged 12-17 Years
July 20, 2022
PharmaShots Weekly Snapshot (August 19 - 23, 2019)
August 26, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.
